Curr Probl Cardiol. 2021 Mar;46(3):100690. doi: 10.1016/j.cpcardiol.2020.100690. Epub 2020 Aug 28.
There is increasing experimental and clinical evidence that inflammation appears to play an important role in atherosclerosis and coronary artery disease. Treatment of coronary artery disease currently involves management of cardiovascular risk factors, lipid-lowering strategies and antiplatelet medications. Inflammation seems to be central to the pathogenesis of atherosclerotic plaque development, instability, and rupture seen in coronary artery disease. Colchicine, a well-known and relatively inexpensive drug, has unique anti-inflammatory properties, which is generating considerable interest in its potential role in reducing cardiovascular morbidity and potentially mortality. This review discusses the mechanism of action of colchicine in preventing and treating atherosclerosis as well as the literature from recent clinical studies supporting its use in coronary artery disease.
越来越多的实验和临床证据表明,炎症似乎在动脉粥样硬化和冠状动脉疾病中起着重要作用。目前,冠状动脉疾病的治疗包括心血管危险因素的管理、降脂策略和抗血小板药物。炎症似乎是动脉粥样硬化斑块发展、不稳定和冠状动脉疾病中所见破裂的发病机制的核心。秋水仙碱是一种众所周知且相对便宜的药物,具有独特的抗炎特性,这使其在降低心血管发病率和死亡率方面的潜在作用引起了极大的关注。本文讨论了秋水仙碱预防和治疗动脉粥样硬化的作用机制,以及支持其在冠状动脉疾病中应用的近期临床研究文献。